A Lancet Neurology review addresses a common dilemma. Bradycardia and conduction abnormalities are frequent in dementia with Lewy bodies, probably from autonomic involvement, and cholinesterase inhibitors are often withheld for fear of worsening them. Yet these drugs are the most effective treatment for the cognitive and neuropsychiatric symptoms.
The authors summarise randomised trial and meta-analysis evidence supporting a favourable cardiac safety profile in this condition, and emerging evidence that patients with pre-existing conduction abnormalities can be treated without more major cardiovascular events. They propose an approach built on baseline cardiac screening and monitoring rather than blanket avoidance.
For clinicians, the shift is from 'bradycardia, so no donepezil' to 'bradycardia, so assess and monitor'. The review does not report new trial data, and severe conduction disease still needs cardiology input.
- Record an ECG and pulse before starting a cholinesterase inhibitor
- Ask about syncope, falls and dizziness
- Seek cardiology input for high-grade AV block or symptomatic bradycardia
- Recheck pulse and ECG after starting and after dose increases
- Review other rate-slowing drugs such as beta-blockers
Why it matters
Blanket avoidance denies many patients the one drug class that clearly helps their symptoms.
Don't overread it
This is an expert review of existing evidence, not a new trial in patients with conduction disease.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free